Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System.

ABSTRACT:

Background

Ceftaroline fosamil is US Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, but it is not known how ceftaroline is being used in real-world settings or how adverse effects (AEs) and mortality compare to clinical trials.

Objective

This study describes ceftaroline use, AEs, and mortality in US Veterans Health Administration (VHA) hospital patients.

Methods

This phase IV, population-based, epidemiologic study analyzed patients ≥18 years old who received one or more ceftaroline doses within 14 days of admission to 69 VHA hospitals in 41 US states/territories from 1 October 2010 to 30 September 2014. VHA repository data were linked using unique patient identifiers. Diagnoses a

SUBMITTER: Britt RS 

PROVIDER: S-EPMC5553123 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature